News Blackstone closes record $6.3bn life sciences fund Blackstone has closed its latest fund – the $6.3bn BXLS VI – saying it is the largest ever private fund for the life sciences sector.
News Obesity-focused biotech Kailera joins IPO queue in US Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.
News Otsuka grows in neuroplastogens with $1.225bn Transcend buy Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.
News Lilly puts up to $2.75bn into Insilico alliance Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.
News Where others missed, AZ's IL-33 drug hits the mark in COPD AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.
News Novartis snaps up food allergy firm Excellergy for $2bn Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.
News ESMO26: VOLGA stirs up perioperative bladder cancer therapy The VOLGA trial shows that Imfinzi and Padcev could be a rival Keytruda+Padcev in perioperative treatment of muscle-invasive bladder cancer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
